Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Cholangiocarcinoma · Bile Duct Neoplasm · Biliary Tract Malignancy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (For more information at the NIH Clinical Center contact National Cancer Institute Referral Office) · 888-624-1937
Study leads
Jonathan M Hernandez, M.D.
Principal Investigator
National Cancer Institute (NCI)